Skip to content
Los Uromigos· @LosUromigos · X·· 3 days agoScore70

enfortumab

Body

De camino a #ESMO26 con novedades importantes en cáncer de vejiga

La Comisión Europea aprueba enfortumab vedotin + pembrolizumab como tratamiento perioperatorio del cáncer de vejiga músculo-invasivo, independientemente de la elegibilidad para cisplatino

Un nuevo escenario terapéutico que dará mucho que hablar en Madrid @OncoAlert

https://www.merck.com/news/european-commission-approves-keytruda-pembrolizumab-plus-padcev-enfortumab-vedotin-ejfv-as-perioperative-treatment-for-adults-with-resectable-muscle-invasive-bladder-cancer-mibc/

1048 views · 13 likes · 10 reposts · 0 replies

Conference abstracts
4733Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905

https://esmocongress.esmo.org
4734Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin

https://esmocongress.esmo.org
4738ROmatched by Rapid oral 1: Genitourinary tumours, renal and urothelial

Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) eligible for cisplatin in the phase 3 KEY

https://esmocongress.esmo.org
4740ROmatched by Rapid oral 1: Genitourinary tumours, renal and urothelial

Enfortumab Vedotin (EV) With or Without Pembrolizumab (P) as First-Line (1L) Treatment for Cisplatin (cis)-Ineligible Locally Advanced Or Metastatic Urothelial Carcinoma (la/mUC): Long-Term Follow-up Analysis from EV-103 Cohorts DE/A and K

https://esmocongress.esmo.org
4742Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

Sacituzumab Govitecan (SG) Combined With Enfortumab Vedotin (EV) and Zimberelimab (ZIM) in Treatment-Naive Metastatic Urothelial Cancer (mUC): Interim Results From Phase 1b TROPHY-U-01 Cohort 7

https://esmocongress.esmo.org
4761PNCT04223856NCT04223856NCT04223856matched by Urothelial cancer

Enfortumab Vedotin Plus Pembrolizumab (EV+P) For Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Updated Exploratory Analysis of EV-302 in Older Patients (pts) and Those With Comorbidities

https://esmocongress.esmo.org

Source: Los Uromigos · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org